Annika Aurora de Goede
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Annika Aurora de Goede has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Michael J. A. M. van Putten
Leiden University Medical Center 1 Department of Human Genetics 2333 ZC Leiden
6 shared publications - | Jules A. A. C. Heuberger
Centre for Human Drug Research Leiden The Netherlands
6 shared publications - Geert Jan Groeneveld
Centre for Human Drug Research (CHDR), Leiden, the Netherlands
5 shared publications - Catherine M. K. E. de Cuba
Centre for Human Drug Research Leiden The Netherlands
4 shared publications - Robert Jan Doll
Centre for Human Drug Research Leiden The Netherlands
4 shared publications Esther M. ter Braack
Department of Clinical Neurophysiology, Technical Medical Centre, University of Twente, Enschede, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 13 May 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Transcranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy
One‐third of epilepsy patients remain treatment‐resistant, underscoring the need for novel anti‐seizure medications (ASMs) and reliable biomarkers of central target engagement. Cortical hyperexcitability is a hallmark of epilepsy, making excitability a valuable pharmacodynamic biomarker for early‐phase drug development supporting go/no‐go decision making. Building upon prior transcranial magnetic stimulation (TMS) work in healthy participants, this study aimed to establish TMS‐derived endpoints as translational biomarkers of ASM effects in patients. In a randomized, double‐blind, placebo‐controlled, two‐way crossover design, patients with generalized epilepsy on levetiracetam (500 mg twice daily; n = 14) or valproic acid (≤1,000 mg/day; levetiracetam‐naïve, n = 12) received a single oral dose of levetiracetam (2000 mg) or placebo. Participants were asked to refrain from their morning ASM dose to minimize background ASM levels while maintaining seizure protection. TMS combined with electromyography (EMG) and electroencephalography (EEG), and resting‐state EEG were performed pre‐dose, 1.5 h, and 3 h post‐dose. Outcomes were analyzed using mixed‐effects analysis of covariance or cluster‐based permutation testing. Levetiracetam significantly reduced motor‐evoked potential (MEP) amplitude, enhanced long‐interval intracortical inhibition (LICI), and increased frontal gamma and beta power, with larger effect sizes in levetiracetam‐naïve patients. These findings were further supported by linear concentration–response relationships for these endpoints. TMS–EEG revealed group‐specific modulation: early TMS‐evoked potential components (P30/N45) in levetiracetam patients vs. later components (N100/P180) in levetiracetam‐naïve patients. These findings build upon prior results, demonstrating that TMS‐based biomarkers are sensitive to levetiracetam's acute effects in epilepsy patients with MEP amplitude, LICI, and frontal beta/gamma power emerging as promising biomarkers, possible also for new ASM development.
- 13 May 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Open AccessTranscranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy
One‐third of epilepsy patients remain treatment‐resistant, underscoring the need for novel anti‐seizure medications (ASMs) and reliable biomarkers of central target engagement. Cortical hyperexcitability is a hallmark of epilepsy, making excitability a valuable pharmacodynamic biomarker for early‐phase drug development supporting go/no‐go decision making. Building upon prior transcranial magnetic stimulation (TMS) work in healthy participants, this study aimed to establish TMS‐derived endpoints as translational biomarkers of ASM effects in patients. In a randomized, double‐blind, placebo‐controlled, two‐way crossover design, patients with generalized epilepsy on levetiracetam (500 mg twice daily; n = 14) or valproic acid (≤1,000 mg/day; levetiracetam‐naïve, n = 12) received a single oral dose of levetiracetam (2000 mg) or placebo. Participants were asked to refrain from their morning ASM dose to minimize background ASM levels while maintaining seizure protection. TMS combined with electromyography (EMG) and electroencephalography (EEG), and resting‐state EEG were performed pre‐dose, 1.5 h, and 3 h post‐dose. Outcomes were analyzed using mixed‐effects analysis of covariance or cluster‐based permutation testing. Levetiracetam significantly reduced motor‐evoked potential (MEP) amplitude, enhanced long‐interval intracortical inhibition (LICI), and increased frontal gamma and beta power, with larger effect sizes in levetiracetam‐naïve patients. These findings were further supported by linear concentration–response relationships for these endpoints. TMS–EEG revealed group‐specific modulation: early TMS‐evoked potential components (P30/N45) in levetiracetam patients vs. later components (N100/P180) in levetiracetam‐naïve patients. These findings build upon prior results, demonstrating that TMS‐based biomarkers are sensitive to levetiracetam's acute effects in epilepsy patients with MEP amplitude, LICI, and frontal beta/gamma power emerging as promising biomarkers, possible also for new ASM development.
- Open Access
- 20 August 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (1) , 147-157
Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti‐epileptic and sedative properties of CBD. A randomized, double‐blind, placebo‐controlled, 3‐way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed‐effects model. CBD did not have significant effects on single pulse and paired pulse TMS‐EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS‐EEG at 3 hours post‐dose for 30 mg CBD, and at 3 and 5 hours post‐dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti‐epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
- 20 August 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (1) , 147-157
Open AccessCannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti‐epileptic and sedative properties of CBD. A randomized, double‐blind, placebo‐controlled, 3‐way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed‐effects model. CBD did not have significant effects on single pulse and paired pulse TMS‐EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS‐EEG at 3 hours post‐dose for 30 mg CBD, and at 3 and 5 hours post‐dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti‐epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
- Open Access
- 9 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 768-778
Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
NMD670 is a first‐in‐class inhibitor of skeletal muscle‐specific chloride channel ClC‐1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC‐1 inhibition enhances muscle excitability, improving muscle contractility and strength. We describe the first‐in‐human, randomized, double‐blind, placebo‐controlled study, which evaluated the safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of NMD670 in healthy male and female subjects. Single‐ascending doses (50–1,600 mg) were administered in a (partial) cross‐over design; multiple‐ascending doses (200–600 mg q.d.; 400 mg b.i.d.) were administered in a parallel design. Differences in pharmacokinetics between males/females and fed/fasted states were evaluated. Pharmacodynamic effects were evaluated using muscle velocity recovery cycles (MVRC) and analyzed using mixed‐effects modeling. NMD670 was generally safe and well‐tolerated in healthy subjects, with the only dose‐related adverse event being myotonia occurring at the highest dose levels tested (single dose of 1,200, and 1,600 mg). Moreover, NMD670 significantly increased the following MVRC parameters after a single dose of 1,200 mg compared with placebo: early supernormality (estimated difference (ED) 2.04; 95% confidence interval (CI) 0.379, 3.70; P = 0.0242); early supernormality after 5 conditioning stimuli (ED 2.51; 95%CI 0.599, 4.41; P = 0.0177); supernormality at 20 ms (ED 2.78; 95%CI 1.377, 4.181; P = 0.0021). Importantly, the results of this study indicate pharmacological target engagement at well‐tolerated dose levels in healthy subjects; firstly, because myotonia was an expected exaggerated on‐target pharmacological effect, and secondly, because the effects on MVRC indicate increased muscle cell excitability. This study in healthy subjects indicates proof‐of‐mechanism and provides a solid base for translation to patients with neuromuscular diseases.
- 9 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 768-778
Open AccessSafety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
NMD670 is a first‐in‐class inhibitor of skeletal muscle‐specific chloride channel ClC‐1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC‐1 inhibition enhances muscle excitability, improving muscle contractility and strength. We describe the first‐in‐human, randomized, double‐blind, placebo‐controlled study, which evaluated the safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of NMD670 in healthy male and female subjects. Single‐ascending doses (50–1,600 mg) were administered in a (partial) cross‐over design; multiple‐ascending doses (200–600 mg q.d.; 400 mg b.i.d.) were administered in a parallel design. Differences in pharmacokinetics between males/females and fed/fasted states were evaluated. Pharmacodynamic effects were evaluated using muscle velocity recovery cycles (MVRC) and analyzed using mixed‐effects modeling. NMD670 was generally safe and well‐tolerated in healthy subjects, with the only dose‐related adverse event being myotonia occurring at the highest dose levels tested (single dose of 1,200, and 1,600 mg). Moreover, NMD670 significantly increased the following MVRC parameters after a single dose of 1,200 mg compared with placebo: early supernormality (estimated difference (ED) 2.04; 95% confidence interval (CI) 0.379, 3.70; P = 0.0242); early supernormality after 5 conditioning stimuli (ED 2.51; 95%CI 0.599, 4.41; P = 0.0177); supernormality at 20 ms (ED 2.78; 95%CI 1.377, 4.181; P = 0.0021). Importantly, the results of this study indicate pharmacological target engagement at well‐tolerated dose levels in healthy subjects; firstly, because myotonia was an expected exaggerated on‐target pharmacological effect, and secondly, because the effects on MVRC indicate increased muscle cell excitability. This study in healthy subjects indicates proof‐of‐mechanism and provides a solid base for translation to patients with neuromuscular diseases.
- Open Access
- 6 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 787-797
TMS and EEG Pharmacodynamic Effects of a Selective Sphingosine‐1‐Phosphate Subtype 1 Receptor Agonist on Cortical Excitability in Healthy Subjects
Current anti‐epileptic drugs lack efficacy, cause many side effects and one third of all patients are treatment‐resistant. Drugs targeting the sphingosine‐1‐phosphate receptor show potential anti‐convulsant effects in animal models and decrease cortical excitability in patients with multiple sclerosis, but available compounds alter lymphocyte trafficking and cause immunosuppression, limiting their clinical anti‐epileptic potential. TRV045 is a selective sphingosine‐1‐phosphate subtype 1 receptor agonist without effects on lymphocyte trafficking, demonstrating efficacy in animal models of epilepsy, with the potential to target abnormal cortical excitability. This randomized, double‐blind, placebo‐controlled, two‐way cross‐over, multiple‐dose study evaluated the effects of TRV045 on cortical excitability in healthy male adults, measured by pharmaco‐electroencephalography and transcranial magnetic stimulation (TMS). Subjects received TRV045 250 mg or placebo, once daily for 4 days, in randomized order. Endpoints were analyzed with a mixed effects model analysis of covariance. Twenty‐five of the 27 subjects completed the study. There was a significant increase in alpha power with eyes open after treatment with TRV045 on Day 1, increasing after 4 days of dosing. Less pronounced significant effects in beta, gamma, and delta power were observed after 4 days. For TMS‐Electromyography there was a non‐significant decreased post‐dose single‐pulse peak‐to‐peak amplitude on Day 1 only, and there were no effects on paired‐pulse parameters. Several significant TMS‐Electroencephalography clusters were seen after 4 days of dosing. These findings show that TRV045 has central nervous system activity with evolving effects following repeated dosing. These data support further studies to elucidate the mechanism of action of TRV045 and its potential anti‐epileptic effects.
- 6 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 787-797
Open AccessTMS and EEG Pharmacodynamic Effects of a Selective Sphingosine‐1‐Phosphate Subtype 1 Receptor Agonist on Cortical Excitability in Healthy Subjects
Current anti‐epileptic drugs lack efficacy, cause many side effects and one third of all patients are treatment‐resistant. Drugs targeting the sphingosine‐1‐phosphate receptor show potential anti‐convulsant effects in animal models and decrease cortical excitability in patients with multiple sclerosis, but available compounds alter lymphocyte trafficking and cause immunosuppression, limiting their clinical anti‐epileptic potential. TRV045 is a selective sphingosine‐1‐phosphate subtype 1 receptor agonist without effects on lymphocyte trafficking, demonstrating efficacy in animal models of epilepsy, with the potential to target abnormal cortical excitability. This randomized, double‐blind, placebo‐controlled, two‐way cross‐over, multiple‐dose study evaluated the effects of TRV045 on cortical excitability in healthy male adults, measured by pharmaco‐electroencephalography and transcranial magnetic stimulation (TMS). Subjects received TRV045 250 mg or placebo, once daily for 4 days, in randomized order. Endpoints were analyzed with a mixed effects model analysis of covariance. Twenty‐five of the 27 subjects completed the study. There was a significant increase in alpha power with eyes open after treatment with TRV045 on Day 1, increasing after 4 days of dosing. Less pronounced significant effects in beta, gamma, and delta power were observed after 4 days. For TMS‐Electromyography there was a non‐significant decreased post‐dose single‐pulse peak‐to‐peak amplitude on Day 1 only, and there were no effects on paired‐pulse parameters. Several significant TMS‐Electroencephalography clusters were seen after 4 days of dosing. These findings show that TRV045 has central nervous system activity with evolving effects following repeated dosing. These data support further studies to elucidate the mechanism of action of TRV045 and its potential anti‐epileptic effects.
- Open Access
- 3 February 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (6) , 2926-2937
Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double‐blind, placebo‐controlled, cross‐over study
Aims: The purpose of this study was to investigate pharmacodynamic effects of drugs targeting cortical excitability using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG) in healthy subjects, to further develop TMS outcomes as biomarkers for proof‐of‐mechanism in early‐phase clinical drug development. Antiepileptic drugs presumably modulate cortical excitability. Therefore, we studied effects of levetiracetam, valproic acid and lorazepam on cortical excitability in a double‐blind, placebo‐controlled, 4‐way cross‐over study.Methods: In 16 healthy male subjects, single‐ and paired‐pulse TMS‐EMG–EEG measurements were performed predose and 1.5, 7 and 24 hours postdose. Treatment effects on motor‐evoked potential, short and long intracortical inhibition and TMS‐evoked potential amplitudes, were analysed using a mixed model ANCOVA and cluster‐based permutation analysis.Results: We show that motor‐evoked potential amplitudes decreased after administration of levetiracetam (estimated difference [ED] −378.4 μV; 95%CI: −644.3, −112.5 μV; P < .01), valproic acid (ED −268.8 μV; 95%CI: −532.9, −4.6 μV; P = .047) and lorazepam (ED −330.7 μV; 95%CI: −595.6, −65.8 μV; P = .02) when compared with placebo. Long intracortical inhibition was enhanced by levetiracetam (ED −60.3%; 95%CI: −87.1%, −33.5%; P < .001) and lorazepam (ED −68.2%; 95%CI: −94.7%, −41.7%; P < .001) at a 50‐ms interstimulus interval. Levetiracetam increased TMS‐evoked potential component N45 (P = .004) in a central cluster and decreased N100 (P < .001) in a contralateral cluster.Conclusion: This study shows that levetiracetam, valproic acid and lorazepam decrease cortical excitability, which can be detected using TMS‐EMG–EEG in healthy subjects. These findings provide support for the use of TMS excitability measures as biomarkers to demonstrate pharmacodynamic effects of drugs that influence cortical excitability.
- 3 February 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (6) , 2926-2937
Open AccessTranscranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double‐blind, placebo‐controlled, cross‐over study
Aims: The purpose of this study was to investigate pharmacodynamic effects of drugs targeting cortical excitability using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG) in healthy subjects, to further develop TMS outcomes as biomarkers for proof‐of‐mechanism in early‐phase clinical drug development. Antiepileptic drugs presumably modulate cortical excitability. Therefore, we studied effects of levetiracetam, valproic acid and lorazepam on cortical excitability in a double‐blind, placebo‐controlled, 4‐way cross‐over study.Methods: In 16 healthy male subjects, single‐ and paired‐pulse TMS‐EMG–EEG measurements were performed predose and 1.5, 7 and 24 hours postdose. Treatment effects on motor‐evoked potential, short and long intracortical inhibition and TMS‐evoked potential amplitudes, were analysed using a mixed model ANCOVA and cluster‐based permutation analysis.Results: We show that motor‐evoked potential amplitudes decreased after administration of levetiracetam (estimated difference [ED] −378.4 μV; 95%CI: −644.3, −112.5 μV; P < .01), valproic acid (ED −268.8 μV; 95%CI: −532.9, −4.6 μV; P = .047) and lorazepam (ED −330.7 μV; 95%CI: −595.6, −65.8 μV; P = .02) when compared with placebo. Long intracortical inhibition was enhanced by levetiracetam (ED −60.3%; 95%CI: −87.1%, −33.5%; P < .001) and lorazepam (ED −68.2%; 95%CI: −94.7%, −41.7%; P < .001) at a 50‐ms interstimulus interval. Levetiracetam increased TMS‐evoked potential component N45 (P = .004) in a central cluster and decreased N100 (P < .001) in a contralateral cluster.Conclusion: This study shows that levetiracetam, valproic acid and lorazepam decrease cortical excitability, which can be detected using TMS‐EMG–EEG in healthy subjects. These findings provide support for the use of TMS excitability measures as biomarkers to demonstrate pharmacodynamic effects of drugs that influence cortical excitability.
- Open Access
- 27 May 2021
- Published by Springer Nature in Translational Psychiatry
- Vol. 11 (1) , 1-10
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation
TAK-653 is a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-positive allosteric modulator being developed as a potential therapeutic for major depressive disorder (MDD). Currently, there are no translational biomarkers that evaluate physiological responses to the activation of glutamatergic brain circuits available. Here, we tested whether noninvasive neurostimulation, specifically single-pulse or paired-pulse motor cortex transcranial magnetic stimulation (spTMS and ppTMS, respectively), coupled with measures of evoked motor response captures the pharmacodynamic effects of TAK-653 in rats and healthy humans. In the rat study, five escalating TAK-653 doses (0.1–50 mg/kg) or vehicle were administered to 31 adult male rats, while measures of cortical excitability were obtained by spTMS coupled with mechanomyography. Twenty additional rats were used to measure brain and plasma TAK-653 concentrations. The human study was conducted in 24 healthy volunteers (23 males, 1 female) to assess the impact on cortical excitability of 0.5 and 6 mg TAK-653 compared with placebo, measured by spTMS and ppTMS coupled with electromyography in a double-blind crossover design. Plasma TAK-653 levels were also measured. TAK-653 increased both the mechanomyographic response to spTMS in rats and the amplitude of motor-evoked potentials in humans at doses yielding similar plasma concentrations. TAK-653 did not affect resting motor threshold or paired-pulse responses in humans. This is the first report of a translational functional biomarker for AMPA receptor potentiation and indicates that TMS may be a useful translational platform to assess the pharmacodynamic profile of glutamate receptor modulators.
- 27 May 2021
- Published by Springer Nature in Translational Psychiatry
- Vol. 11 (1) , 1-10
Open AccessTranscranial magnetic stimulation as a translational biomarker for AMPA receptor modulation
TAK-653 is a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-positive allosteric modulator being developed as a potential therapeutic for major depressive disorder (MDD). Currently, there are no translational biomarkers that evaluate physiological responses to the activation of glutamatergic brain circuits available. Here, we tested whether noninvasive neurostimulation, specifically single-pulse or paired-pulse motor cortex transcranial magnetic stimulation (spTMS and ppTMS, respectively), coupled with measures of evoked motor response captures the pharmacodynamic effects of TAK-653 in rats and healthy humans. In the rat study, five escalating TAK-653 doses (0.1–50 mg/kg) or vehicle were administered to 31 adult male rats, while measures of cortical excitability were obtained by spTMS coupled with mechanomyography. Twenty additional rats were used to measure brain and plasma TAK-653 concentrations. The human study was conducted in 24 healthy volunteers (23 males, 1 female) to assess the impact on cortical excitability of 0.5 and 6 mg TAK-653 compared with placebo, measured by spTMS and ppTMS coupled with electromyography in a double-blind crossover design. Plasma TAK-653 levels were also measured. TAK-653 increased both the mechanomyographic response to spTMS in rats and the amplitude of motor-evoked potentials in humans at doses yielding similar plasma concentrations. TAK-653 did not affect resting motor threshold or paired-pulse responses in humans. This is the first report of a translational functional biomarker for AMPA receptor potentiation and indicates that TMS may be a useful translational platform to assess the pharmacodynamic profile of glutamate receptor modulators.
- Open Access
- 4 May 2020
- Published by Springer Nature in Brain Topography
- Vol. 33 (4) , 425-437
Spatiotemporal Dynamics of Single and Paired Pulse TMS-EEG Responses
For physiological brain function a particular balance between excitation and inhibition is essential. Paired pulse transcranial magnetic stimulation (TMS) can estimate cortical excitability and the relative contribution of inhibitory and excitatory networks. Combining TMS with electroencephalography (EEG) enables additional assessment of the spatiotemporal dynamics of neuronal responses in the stimulated brain. This study aims to evaluate the spatiotemporal dynamics and stability of single and paired pulse TMS-EEG responses, and assess long intracortical inhibition (LICI) at the cortical level. Twenty-five healthy subjects were studied twice, approximately one week apart. Manual coil positioning was applied in sixteen subjects and robot-guided positioning in nine. Both motor cortices were stimulated with 50 single pulses and 50 paired pulses at each of the five interstimulus intervals (ISIs): 100, 150, 200, 250 and 300 ms. To assess stability and LICI, the intraclass correlation coefficient and cluster-based permutation analysis were used. We found great resemblance in the topographical distribution of the characteristic TMS-EEG components for single and paired pulse TMS. Stimulation of the dominant and non-dominant hemisphere resulted in a mirrored spatiotemporal dynamics. No significant effect on the TMS-EEG responses was found for either stimulated hemisphere, time or coil positioning method, indicating the stability of both single and paired pulse TMS-EEG responses. For all ISIs, LICI was characterized by significant suppression of the late N100 and P180 components in the central areas, without affecting the early P30, N45 and P60 components. These observations in healthy subjects can serve as reference values for future neuropsychiatric and pharmacological studies.
- 4 May 2020
- Published by Springer Nature in Brain Topography
- Vol. 33 (4) , 425-437
Open AccessSpatiotemporal Dynamics of Single and Paired Pulse TMS-EEG Responses
For physiological brain function a particular balance between excitation and inhibition is essential. Paired pulse transcranial magnetic stimulation (TMS) can estimate cortical excitability and the relative contribution of inhibitory and excitatory networks. Combining TMS with electroencephalography (EEG) enables additional assessment of the spatiotemporal dynamics of neuronal responses in the stimulated brain. This study aims to evaluate the spatiotemporal dynamics and stability of single and paired pulse TMS-EEG responses, and assess long intracortical inhibition (LICI) at the cortical level. Twenty-five healthy subjects were studied twice, approximately one week apart. Manual coil positioning was applied in sixteen subjects and robot-guided positioning in nine. Both motor cortices were stimulated with 50 single pulses and 50 paired pulses at each of the five interstimulus intervals (ISIs): 100, 150, 200, 250 and 300 ms. To assess stability and LICI, the intraclass correlation coefficient and cluster-based permutation analysis were used. We found great resemblance in the topographical distribution of the characteristic TMS-EEG components for single and paired pulse TMS. Stimulation of the dominant and non-dominant hemisphere resulted in a mirrored spatiotemporal dynamics. No significant effect on the TMS-EEG responses was found for either stimulated hemisphere, time or coil positioning method, indicating the stability of both single and paired pulse TMS-EEG responses. For all ISIs, LICI was characterized by significant suppression of the late N100 and P180 components in the central areas, without affecting the early P30, N45 and P60 components. These observations in healthy subjects can serve as reference values for future neuropsychiatric and pharmacological studies.
- 1 July 2019
- Published by American Physiological Society in Journal of Neurophysiology
- Vol. 122 (1) , 325-335
Infraslow activity as a potential modulator of corticomotor excitability
Fluctuations in cortical excitability are a candidate mechanism involved in the trial-to-trial variation of motor evoked potentials (MEPs) to transcranial magnetic stimulation (TMS). We explore whether infraslow EEG activity (<0.1 Hz) modulates corticomotor excitability by evaluating the presence of temporal and phase clustering of TMS-induced MEPs. In addition, we evaluate the dependence of MEP amplitude on the phase of the infraslow activity. Twenty-three subjects were stimulated at an intensity above the resting motor threshold (rMT) and ten at the rMT. We evaluated whether temporal and phase clustering of MEP size and MEP generation were present, using 1,000 surrogates with a similar amplitude or occurrence distribution. To evaluate the MEP amplitude dependence, we used the least-square method to approximate the linear circular data by fitting a sine function. We observed significant temporal clustering at a group level, in all individual subjects stimulated at rMT and in the majority of those stimulated above rMT, suggesting underlying determinism of corticomotor excitability instead of randomly generated fluctuations. The majority of subjects showed significant phase clustering for MEP size and for MEP occurrence, and significant phase clustering was found at the group level. Furthermore, in approximately one-quarter to one-half of the subjects we found a significant correlation and dependence of MEP amplitude on the phase of infraslow activity, respectively. Although other mechanisms very likely contribute as well, our findings seem to suggest that infraslow activity is involved in the variability of cortical excitability and TMS-induced responses.NEW & NOTEWORTHY Cortical excitability measures are highly variable during transcranial magnetic stimulation. Although ongoing brain oscillations are assumed to modulate excitability, no consistent associations are found for the traditional frequency bands. We focus on the role of infraslow EEG activity, defined as rhythms with frequencies < 0.1 Hz. We provide experimental evidence suggesting that infraslow activity most likely modulates corticomotor excitability and that response variation could be reduced when stimulation is targeted at a specific infraslow phase.
- 1 July 2019
- Published by American Physiological Society in Journal of Neurophysiology
- Vol. 122 (1) , 325-335
Infraslow activity as a potential modulator of corticomotor excitability
Fluctuations in cortical excitability are a candidate mechanism involved in the trial-to-trial variation of motor evoked potentials (MEPs) to transcranial magnetic stimulation (TMS). We explore whether infraslow EEG activity (<0.1 Hz) modulates corticomotor excitability by evaluating the presence of temporal and phase clustering of TMS-induced MEPs. In addition, we evaluate the dependence of MEP amplitude on the phase of the infraslow activity. Twenty-three subjects were stimulated at an intensity above the resting motor threshold (rMT) and ten at the rMT. We evaluated whether temporal and phase clustering of MEP size and MEP generation were present, using 1,000 surrogates with a similar amplitude or occurrence distribution. To evaluate the MEP amplitude dependence, we used the least-square method to approximate the linear circular data by fitting a sine function. We observed significant temporal clustering at a group level, in all individual subjects stimulated at rMT and in the majority of those stimulated above rMT, suggesting underlying determinism of corticomotor excitability instead of randomly generated fluctuations. The majority of subjects showed significant phase clustering for MEP size and for MEP occurrence, and significant phase clustering was found at the group level. Furthermore, in approximately one-quarter to one-half of the subjects we found a significant correlation and dependence of MEP amplitude on the phase of infraslow activity, respectively. Although other mechanisms very likely contribute as well, our findings seem to suggest that infraslow activity is involved in the variability of cortical excitability and TMS-induced responses.NEW & NOTEWORTHY Cortical excitability measures are highly variable during transcranial magnetic stimulation. Although ongoing brain oscillations are assumed to modulate excitability, no consistent associations are found for the traditional frequency bands. We focus on the role of infraslow EEG activity, defined as rhythms with frequencies < 0.1 Hz. We provide experimental evidence suggesting that infraslow activity most likely modulates corticomotor excitability and that response variation could be reduced when stimulation is targeted at a specific infraslow phase.
- 20 February 2019
- Published by University Library/University of Twente
Multimodal TMS
- Open Access
- 17 July 2018
- Published by Springer Nature in Brain Topography
- Vol. 32 (1) , 17-27
Resting Motor Threshold, MEP and TEP Variability During Daytime
Humans show a variation in physiological processes during the day. To reliably assess (changes in) cortical excitability with transcranial magnetic stimulation (TMS), it is relevant to know the natural variation in TMS readouts during the day. In case of significant daytime variations, this should be taken into account when scheduling (follow-up) measurements. This study aims to evaluate the influence of the time of day on the resting motor threshold (RMT), motor evoked potential (MEP) and TMS evoked potential (TEP) in healthy controls. TMS–EMG–EEG was recorded in 16 healthy subjects. At both motor cortices, we administered 75 pulses at an intensity of 110% RMT. Subjects were stimulated during five sessions in one day (8:00 AM, 10:30 AM, 1:00 PM, 3:30 PM and 6:00 PM) while keeping the stimulation intensity constant. We compared the TEP waveforms between the five sessions with a cluster-based permutation analysis, and the RMT and MEP amplitude with rmANOVA. In general there were no significant differences between the five sessions in the RMT, MEP amplitude or TEP. Only for the left side, N100 amplitude was larger at 3:30 PM than 10:30 AM. The standard deviation of the P30 and N100 amplitude was significantly higher between subjects within one session than within single subjects during the day. The TEP is highly reproducible during the day, with a low intra-individual variation compared to the inter-individual variation. In addition, we found no significant variation of the RMT and MEP amplitude between multiple sessions on one day.
- 17 July 2018
- Published by Springer Nature in Brain Topography
- Vol. 32 (1) , 17-27
Open AccessResting Motor Threshold, MEP and TEP Variability During Daytime
Humans show a variation in physiological processes during the day. To reliably assess (changes in) cortical excitability with transcranial magnetic stimulation (TMS), it is relevant to know the natural variation in TMS readouts during the day. In case of significant daytime variations, this should be taken into account when scheduling (follow-up) measurements. This study aims to evaluate the influence of the time of day on the resting motor threshold (RMT), motor evoked potential (MEP) and TMS evoked potential (TEP) in healthy controls. TMS–EMG–EEG was recorded in 16 healthy subjects. At both motor cortices, we administered 75 pulses at an intensity of 110% RMT. Subjects were stimulated during five sessions in one day (8:00 AM, 10:30 AM, 1:00 PM, 3:30 PM and 6:00 PM) while keeping the stimulation intensity constant. We compared the TEP waveforms between the five sessions with a cluster-based permutation analysis, and the RMT and MEP amplitude with rmANOVA. In general there were no significant differences between the five sessions in the RMT, MEP amplitude or TEP. Only for the left side, N100 amplitude was larger at 3:30 PM than 10:30 AM. The standard deviation of the P30 and N100 amplitude was significantly higher between subjects within one session than within single subjects during the day. The TEP is highly reproducible during the day, with a low intra-individual variation compared to the inter-individual variation. In addition, we found no significant variation of the RMT and MEP amplitude between multiple sessions on one day.